Genasense CLL Trial Meets Primary Endpoint, But Survival Benefit Not Yet Shown

Genta believes that the lack of a survival benefit seen in a Phase III trial of Genasense in chronic lymphocytic leukemia reflects the relatively short follow-up time available for analysis, CEO Raymond Warrell said during a Nov. 9 earnings call